Clinical value of serum squamous cell carcinoma antigen in the management of sinonasal inverted papilloma

Ryuji Yasumatsu, Torahiko Nakashima, Muneyuki Masuda, Yuichiro Kuratomi, Hideki Shiratsuchi, Naoya Hirakawa, Kichinobu Tomita, Tomoya Yamamoto, Shizuo Komune

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

Background. Although sinonasal inverted papilloma (IP) is a rare benign tumor, it has a tendency to recur and is sometimes associated with squamous cell carcinoma (SCC). Therefore, postoperative long-term follow-up of these patients is recommended. We previously reported that serum SCC antigen might be a useful tumor marker for sinonasal IP. In this study, we investigated whether serum SCC antigen level has a correlation with disease status and is useful in the early detection of recurrent disease. Methods. Blood samples for the analysis of serum SCC antigen were taken from 28 IP patients before and after surgical treatment. Results. Twenty-five (89%) of 28 cases showed evaluated serum SCC antigen levels above the upper limit. This marker level decreased in all cases after surgical resection. Four of these patients had a recurrence. None of the patients with recurrent tumor showed symptoms at the time of detection of their recurrent tumor, and recurrence was discovered from elevated levels of SCC antigen. Conclusions. Serum SCC antigen level has a correlation with disease status of IP and has a potential to serve as a useful tool for monitoring the course of disease. SCC antigen is a reliable tumor marker in the management of sinonasal IPs.

Original languageEnglish
Pages (from-to)44-48
Number of pages5
JournalHead and Neck
Volume27
Issue number1
DOIs
Publication statusPublished - Jan 1 2005

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'Clinical value of serum squamous cell carcinoma antigen in the management of sinonasal inverted papilloma'. Together they form a unique fingerprint.

Cite this